RDH10: A Potential Drug Target for Embryonic and Adult Diseases

Target Name: RDH10

NCBI ID: G157506

RDH10

RDH10: A Potential Drug Target for Embryonic and Adult Diseases

RDH10, also known as RDH10-HUMAN, is a gene that encodes a protein known as RGHP in humans. RGHP is an extracellular vesicle that is widely present in embryos and adults and is mainly involved in Material transport and signal transmission between cells. In recent years, scientists have discovered that RDH10 plays an important role in many diseases and regard it as a potential drug target or biomarker. This article will review the current research status, mechanism of action and possibility of RDH10 as a drug target.

1. Research status of RDH10

RDH10 was originally discovered in 1996 by Japanese scientists. Since then, through in-depth research on the expression and function of this gene in various animals and humans, scientists have discovered that RDH10 plays an important role in embryos and adults. Many studies have found that RDH10 expression levels change during embryonic development, thereby affecting the differentiation and development of embryonic organs. In adults, the expression level of RDH10 is closely related to the occurrence and development of various diseases, such as neurodegenerative diseases, tumors, etc.

2. Mechanism of action of RDH10

RDH10, as an extracellular vesicle protein, plays an important role in intercellular material transport and signal transmission. Research shows that RDH10 plays a key role in cell-to-cell signaling. For example, scientists have discovered that RDH10 can interact with some proteins and thereby participate in intercellular signaling. In addition, RDH10 can also serve as a receptor that interacts with some molecules, thereby participating in intercellular material transport.

3. The possibility of RDH10 as a drug target

In recent years, scientists have conducted in-depth research on the drug targets of RDH10 and discovered its possibility as a potential drug target. Currently, a variety of drugs that inhibit RDH10 expression have entered clinical research, such as anti-tumor drugs and anti-neurodegenerative disease drugs. The mechanisms of action of these drugs are related to the functions of RDH10, such as inhibiting cell growth, division and apoptosis.

In addition, scientists have also discovered that RDH10 plays an important role as a gene therapy target. By introducing normal genes into patients, the expression level of RDH10 in patients can be effectively increased, thereby improving the symptoms of patients with neurodegenerative diseases.

4. Conclusion

RDH10, as an extracellular vesicle protein widely present in embryos and adults, plays an important role in a variety of diseases. Its mechanism of action mainly involves intercellular material transport and signal transmission. In recent years, scientists have discovered the drug target properties of RDH10 and studied it as a potential drug target. In the future, scientists will continue to study the function and mechanism of RDH10 in depth and explore more of its application value in medicine.

Protein Name: Retinol Dehydrogenase 10

Functions: Retinol dehydrogenase with a clear preference for NADP. Converts all-trans-retinol to all-trans-retinal. Has no detectable activity towards 11-cis-retinol, 9-cis-retinol and 13-cis-retinol

The "RDH10 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RDH10 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets